SG Americas Securities LLC Has $756,000 Stake in Natera, Inc. (NASDAQ:NTRA)

SG Americas Securities LLC trimmed its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 39.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,775 shares of the medical research company’s stock after selling 3,163 shares during the period. SG Americas Securities LLC’s holdings in Natera were worth $756,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Quarry LP grew its position in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the period. Versant Capital Management Inc grew its position in shares of Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares during the period. Covestor Ltd grew its position in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. GAMMA Investing LLC grew its position in shares of Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the period. Finally, True Wealth Design LLC bought a new position in shares of Natera in the 3rd quarter valued at about $57,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 4,858 shares of Natera stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $166.59, for a total value of $809,294.22. Following the transaction, the insider now owns 114,912 shares in the company, valued at $19,143,190.08. The trade was a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 4,728 shares of Natera stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $146.41, for a total value of $692,226.48. Following the completion of the transaction, the chief executive officer now owns 185,034 shares in the company, valued at $27,090,827.94. This trade represents a 2.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 241,680 shares of company stock valued at $40,102,873 over the last three months. 7.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Sanford C. Bernstein lifted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, January 10th. Guggenheim boosted their target price on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Robert W. Baird boosted their target price on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Finally, Craig Hallum upped their price objective on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $165.88.

Natera Price Performance

NASDAQ NTRA opened at $168.22 on Thursday. Natera, Inc. has a 12 month low of $64.74 and a 12 month high of $183.00. The stock has a market cap of $22.21 billion, a price-to-earnings ratio of -95.58 and a beta of 1.65. The company’s 50 day moving average is $166.56 and its two-hundred day moving average is $137.43. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period last year, the firm posted ($0.95) EPS. The company’s revenue was up 63.9% on a year-over-year basis. As a group, research analysts anticipate that Natera, Inc. will post -1.56 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.